The White House has no immediate plans to require insurance companies to cover in vitro fertilization (IVF), despite U.S. President Donald Trump’s campaign pledge to expand access to fertility treatments, according to The Washington Post.
Earlier this year, President Trump signed an executive order aimed at expanding IVF access and reducing treatment costs for Americans seeking fertility care. The order directed federal agencies to find ways to make the popular treatment more affordable and accessible. However, White House officials say legal constraints prevent them from mandating insurance coverage without Congressional approval.
While the administration maintains that increasing IVF access is still a policy priority, no legislation has been introduced in Congress to address the insurance coverage gap. Without such a bill, the federal government cannot compel private insurers to include IVF in their health plans.
IVF has become an increasingly sought-after solution for couples and individuals facing infertility, but the high cost—often exceeding $15,000 per cycle in the U.S.—remains a major barrier. Advocates argue that insurance mandates could help millions access treatment, while opponents cite concerns over cost implications for the healthcare system.
The issue has drawn renewed national attention following several state-level legislative battles over fertility treatment access. In some states, lawmakers have moved to protect or expand IVF coverage, while others have faced legal and political challenges that could limit availability.
Reuters was unable to independently verify the Washington Post report, and the White House did not respond to a request for comment. For now, the future of federally mandated IVF insurance coverage remains uncertain, leaving millions of hopeful parents in limbo as the debate over fertility rights and healthcare policy continues.


U.S. Government Enters Brief Shutdown as Congress Delays Funding Deal
Why Trump’s new pick for Fed chair hit gold and silver markets – for good reasons
U.S. and Israeli Military Leaders Hold Pentagon Talks as Tensions With Iran Escalate
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Russian Drone Strike Kills Miners as Ukraine Pushes for Peace Talks Amid Energy Crisis
Peter Mandelson Resigns from Labour Party Amid Renewed Jeffrey Epstein Links
Syria-Kurdish Ceasefire Marks Historic Step Toward National Unity
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Keir Starmer Urges Prince Andrew to Testify in U.S. Epstein Investigation
Kevin Warsh’s Fed Nomination Raises Questions Over Corporate Ties and U.S.–South Korea Trade Tensions
Rafah Border Crossing to Reopen for Palestinians as Israel Coordinates with Egypt and EU
Christian Menefee Wins Texas Special Election, Narrowing GOP House Majority
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 



